• Quadmedicine applied to South Korea’s MFDS on Oct. 29, 2026, for Phase 1 trial authorization for its Teriqu patch osteoporosis treatment.
• The planned trial will enroll 36 adult women to compare the patch with Teribone injections.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quadmedicine Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261030901231), on October 30, 2026, and is solely responsible for the information contained therein.